Pathogen safety of long-term treatments for bleeding disorders: (Un)Predictable risks and evolving threats

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 7, 2013, Pages 779-793

  Di Minno, Giovanni ^a   Canaro, Mariana ^b   Ironside, Jamesw ^c   Navarro, David ^d   Perno, Carlof ^e   Tiede, Andreas ^f   Guertler, Lutz ^g  

^a Department of Clinical Experimental Medicine   (Italy)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

bleeding disorders; blood safety; emerging infectious agent(s)

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ADVATE RAHF; ALEVIATE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; FACTOR 8Y; FIBRINOGEN; GREENEIGHT; HAEMONINE; HAEMOSOLVATE FVIII; HEMO B RAAS; HEMOFIL M AHF; HEMORAAS IP AND HEMORAAS HP SD PLUS H; HEMORAAS SD PLUS H; OCTANATE; OCTANATIV M; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINATE RAHF; TBSF FIX; TBSF FVIII; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANAPHYLAXIS; ARBOVIRUS; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE DISORDER; BABESIA; BACTERIUM CONTAMINATION; BLEEDING DISORDER; BLOOD SAFETY; BLOOD SUBSTITUTION; BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; CHIKUNGUNYA ALPHAVIRUS; CHRONIC WASTING DISEASE; CIRCOVIRUS; CYTOMEGALOVIRUS; DENGUE VIRUS; DISEASE TRANSMISSION; ENCEPHALITIS VIRUS; ENTEROVIRUS; FEVER; HEMOLYSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IATROGENIC DISEASE; IMMUNOLOGICAL TOLERANCE; INFECTION CONTROL; INFECTION RISK; IRON OVERLOAD; LEISHMANIA; LIFE EXPECTANCY; LONG TERM CARE; MEDLINE; MICROCHIMERISM; PATHOGEN LOAD; PATHOGENESIS; PLASMODIUM; PRIORITY JOURNAL; PRODUCT SAFETY; PROPHYLAXIS; TRANSFUSION RELATED ACUTE LUNG INJURY; TRYPANOSOMA CRUZI; VARIANT CREUTZFELDT JAKOB DISEASE; VIRUS; VIRUS INFECTION; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; HEMOPHILIA A; HUMANS; INFECTION;

EID: 84885036542     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1354420     Document Type: Article

References (76)

1. Srivastava A., Brewer A. K., Mauser-Bunschoten E. P., et al. Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia: 2013; 19 1 e1 e47
2. Miller C. H., Benson J., Ellingsen D., et al. Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia: 2012; 18 3 375 382
3. Schwarz J., Astermark J., Menius E. D., et al. Hemophilia Inhibitor Genetics Study Combined Cohort. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia: 2013; 19 1 113 118
4. Lippi G., Favaloro E. J., Montagnana M., Manzato F., Guidi G. C., Franchini M. Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis: 2011; 22 3 160 166
5. Kessler C. M. New perspectives in hemophilia treatment. Hematology (Am Soc Hematol Educ Program): 2005; 429 435
6. Brooker M. Registry of Clotting Factor Concentrates. 9th ed. Montreal, Quebec, Canada World Federation of Hemophilia (WFH); 2012. http://www1.wfh.org/ publications/files/pdf-1227.pdf. Accessed May 1, 2013
7. Franchini M., Mannucci P. M. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis: 2012; 7 1 24
8. Tagliaferri A., Rivolta G. F., Iorio A., et al. Italian Association of Hemophilia Centers. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia: 2010; 16 3 437 446
9. Chorba T. L., Holman R. C., Clarke M. J., Evatt B. L. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol: 2001; 66 4 229 240 (Pubitemid 32210289)
10. Plug I., Van Der Bom J. G., Peters M., et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost: 2006; 4 3 510 516
11. Darby S. C., Kan S. W., Spooner R. J., et al. UK Haemophilia Centre Doctors' Organisation. The impact of HIV on mortality rates in the complete UK haemophilia population. AIDS: 2004; 18 3 525 533
12. Fransen van de Putte D. E., Fischer K., Pulles A. E., et al. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res: 2012; 130 2 157 162
13. Yee T. T., Lee C. A. Transfusion-transmitted infection in hemophilia in developing countries. Semin Thromb Hemost: 2005; 31 5 527 537 (Pubitemid 41642566)
14. Branch A. D., Van Natta M. L., Vachon M. L., Dieterich D. T., Meinert C. L., Jabs D. A.; Studies of the Ocular Complications of AIDS Research Group. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis: 2012; 55 1 137 144
15. Franchini M., Tagliaferri A., Mengoli C., Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol: 2012; 81 1 82 93
16. Goedert J. J., Chen B. E., Preiss L., Aledort L. M., Rosenberg P. S. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. Am J Epidemiol: 2007; 165 12 1443 1453 (Pubitemid 47234309)
17. Svicher V., Cento V., Bernassola M., et al. Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Res: 2012; 93 1 86 93
18. Powell J. S. Recombinant factor VIII in the management of hemophilia A: current use and future promise. Ther Clin Risk Manag: 2009; 5 2 391 402
19. Sharma S., Sharma P., Tyler L. N. Transfusion of blood and blood products: indications and complications. Am Fam Physician: 2011; 83 6 719 724
20. Wagner S. Transfusion-related bacterial sepsis. Curr Opin Hematol: 1997; 4 6 464 469 (Pubitemid 27494199)
21. Pittman M. A study of bacteria implicated in transfusion reactions and of bacteria isolated from blood products. J Lab Clin Med: 1953; 42 2 273 288
22. Goel R., Krishnamurti L. Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates. Haemophilia: 2012; 18 5 688 692
23. Rothschild C., D'Oiron R., Borel-Derlon A., et al. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study. Haemophilia: 2013; 19 2 281 286
24. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol: 2007; 138 3 305 315
25. Ghosh K., Shetty S. Immune response to FVIII in hemophilia A: an overview of risk factors. Clin Rev Allergy Immunol: 2009; 37 2 58 66
26. Makris M., Hay C. R., Gringeri A., D'Oiron R. How I treat inhibitors in haemophilia. Haemophilia: 2012; 18 04 48 53
27. Iorio A., Halimeh S., Holzhauer S., et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost: 2010; 8 6 1256 1265
28. Mannucci P. M., Mancuso M. E., Santagostino E. How we choose factor VIII to treat hemophilia. Blood: 2012; 119 18 4108 4114
29. Ghio M., Contini P., Ottonello L., et al. Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost: 2003; 89 2 365 373
30. Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus: 2010; 8 4 292 296
31. Goodnough L. T., Shander A., Brecher M. E. Transfusion medicine: looking to the future. Lancet: 2003; 361 9352 161 169 (Pubitemid 36092025)
32. Ceccherini-Nelli L., Filipponi F., Mosca F., Campa M. The risk of contracting an infectious disease from blood transfusion. Transplant Proc: 2004; 36 3 680 682 (Pubitemid 38534358)
33. Glynn S. A., Busch M. P., Dodd R. Y., et al. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion: 2013; 53 2 438 454
34. Trimble S. R., Parker C. S., Grant A. M., Soucie J. M., Reyes N. Assessing emerging infectious threats to blood safety for the blood disorders community. Am J Prev Med: 2010; 38 (4, Suppl): S468 S474
35. Webby R., Hoffmann E., Webster R. Molecular constraints to interspecies transmission of viral pathogens. Nat Med: 2004; 10 (12, Suppl): S77 S81 (Pubitemid 40018230)
36. Lim J. K., Murphy P. M. Chemokine control of West Nile virus infection. Exp Cell Res: 2011; 317 5 569 574
37. Sahlberg A. S., Granfors K., Penttinen M. A. HLA-B27 and host-pathogen interaction. Adv Exp Med Biol: 2009; 649 235 244
38. Kaur P., Basu S. Transfusion-transmitted infections: existing and emerging pathogens. J Postgrad Med: 2005; 51 2 146 151 (Pubitemid 40982246)
39. Wolfe N. D., Dunavan C. P., Diamond J. Origins of major human infectious diseases. Nature: 2007; 447 7142 279 283 (Pubitemid 46788835)
40. Zappa A., Amendola A., Romanò L., Zanetti A. Emerging and re-emerging viruses in the era of globalisation. Blood Transfus: 2009; 7 3 167 171
41. Woolhouse M. E., Haydon D. T., Antia R. Emerging pathogens: the epidemiology and evolution of species jumps. Trends Ecol Evol: 2005; 20 5 238 244 (Pubitemid 40588908)
42. Chamberland M. E. Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products? Clin Infect Dis: 2002; 34 6 797 805 (Pubitemid 34194851)
43. Grillberger L., Kreil T. R., Nasr S., Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J: 2009; 4 2 186 201
44. Dodd R. Y., Leiby D. A. Emerging infectious threats to the blood supply. Annu Rev Med: 2004; 55 191 207 (Pubitemid 38316723)
45. Stramer S. L., Hollinger F. B., Katz L. M., et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion: 2009; 49 02 1S 29S
46. Smolinski S., Hamburg M. A., Lederberg J. Microbial threats to health: emergence, detection, and response. Washington, DC National Academies Press: 2003
47. Hughes R. A., Swan A. V., van Doorn P. A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev: 2012; 7 CD002063
48. Ludlam C. A., Powderly W. G., Bozzette S., et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet: 2006; 367 9506 252 261 (Pubitemid 43107671)
49. Grazzini G., Liumbruno G. M., Pupella S., et al. West Nile virus in Italy: a further threat to blood safety, a further challenge to the blood system. Blood Transfus: 2008; 6 4 235 237
50. Ludlam C. A., Turner M. L. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol: 2006; 132 1 13 24 (Pubitemid 43381566)
51. Liumbruno G. M., Calteri D., Petropulacos K., et al. The Chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus: 2008; 6 4 199 210
52. Sheldon J., Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother: 2008; 61 4 766 768 (Pubitemid 351426057)
53. Stramer S. L., Zou S., Notari E. P., et al. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Transfusion: 2012; 52 2 440 446
54. Sharp C. P., Lail A., Donfield S., Gomperts E. D., Simmonds P. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion: 2012; 52 7 1482 1489
55. Soucie J. M., De Staercke C., Monahan P. E., et al. the US Hemophilia Treatment Center Network. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion: 2013; 53 6 1217 1225
56. Brown P. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia: 2007; 13 05 33 40 (Pubitemid 350253402)
57. Hewitt P. E., Llewelyn C. A., Mackenzie J., Will R. G. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiolgoical Review Study. Vox Sang: 2006; 91 3 221 230 (Pubitemid 44337279)
58. Wroe S. J., Pal S., Siddique D., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet: 2006; 368 9552 2061 2067 (Pubitemid 44855106)
59. Peden A., McCardle L., Head M. W., et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia: 2010; 16 2 296 304
60. Allain J. P., Stramer S. L., Carneiro-Proietti A. B., et al. Transfusion-transmitted infectious diseases. Biologicals: 2009; 37 2 71 77
61. Stein J., Besley J., Brook C., et al. Risk-based decision-making for blood safety: preliminary report of a consensus conference. Vox Sang: 2011; 101 4 277 281
62. Bolton-Maggs P. H. Optimal haemophilia care versus the reality. Br J Haematol: 2006; 132 6 671 682
63. Evatt B. L., Austin H., Leon G., Ruiz-Sáez A., De Bosch N. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia: 1999; 5 5 295 300 (Pubitemid 29495704)
64. Spannagl M., Joch Ch, Heindl B. [Safety of plasma-derived factor concentrates: an example of pharmacovigilance with fibrinogen and factor XIII-concentrate]. Hamostaseologie: 2006; 26 3 01 S36 S40
65. Lusher J. M., Scharrer I. Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer. Int J Hematol: 2009; 90 4 446 454
66. Mackay G. A., Knight R. S., Ironside J. W. The molecular epidemiology of variant CJD. Int J Mol Epidemiol Genet: 2011; 2 3 217 227
67. Bishop M. T., Pennington C., Heath C. A., Will R. G., Knight R. S. PRNP variation in UK sporadic and variant Creutzfeldt Jakob disease highlights genetic risk factors and a novel non-synonymous polymorphism. BMC Med Genet: 2009; 10 146
68. Mead S., Poulter M., Uphill J., et al. Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol: 2009; 8 1 57 66
69. Bishop M. T., Kovacs G. G., Sanchez-Juan P., Knight R. S. Cathepsin D SNP associated with increased risk of variant Creutzfeldt-Jakob disease. BMC Med Genet: 2008; 9 31
70. Franchini M., Tagliaferri A., Mannucci P. M. The management of hemophilia in elderly patients. Clin Interv Aging: 2007; 2 3 361 368
71. Mannucci P. M., Schutgens R. E., Santagostino E., Mauser-Bunschoten E. P. How I treat age-related morbidities in elderly persons with hemophilia. Blood: 2009; 114 26 5256 5263
72. Knight R., Stanley S., Wong M., Dolan G. Hemophilia therapy and blood-borne pathogen risk. Semin Thromb Hemost: 2006; 32 02 3 9
73. Tapper M. L. Emerging viral diseases and infectious disease risks. Haemophilia: 2006; 12 01 3 7, discussion 26-28
74. Grard G., Fair J. N., Lee D., et al. A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog: 2012; 8 9 e1002924
75. Health Protection Agency. Summary results of the second national survey of abnormal prion protein prevalence in archived appendix specimens. Health Protection Report 2012. http://www.hpa.org.uk/hpr/archives/2012/news3212. htm#bnrmlprn. Published August 2012. Accessed 5 June 2013.
76. Katz L. M. Transfusion safety in the 21st century: how tightly should the blood community close the window(s)? J Infect Dis: 2008; 198 9 1258 1261